Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study

Background Fibroblast growth factor 23 ( FGF 23) is emerging as a novel biomarker of bone metabolism, chronic kidney disease, and cardiovascular disease ( CVD ). However, its clinical correlates and potential predictive role in a community‐based setting are incompletely understood. Methods and Results We evaluated participants of the Framingham Heart Study (seventh examination cycle of the Offspring cohort plus second examination cycle of the...